Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models.

Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models.
复制标题

DOI:
10.1126/sciadv.abc5911
复制
发表时间:
2020-11
期刊:
影响因子:
13.6
通讯作者:
Sahay G
Sahay G
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Mukherjee A;MacDonald KD;Kim J;Henderson MI;Eygeris Y;Sahay G

文献摘要

参考文献

被引文献

相似文献

用于治疗囊性纤维化的纳米颗粒递送的ENaC抑制性mRNA。囊性纤维化(CF)是由氯离子传导CF跨膜传导调节因子(CFTR)基因突变引起的。CF中的气道脱水和粘膜纤毛清除受损被认为导致紧张性上皮钠通道(ENaC)活性,其驱动阿米洛利敏感的产电钠吸收。通过抑制ENaC减少钠吸收可以逆转气道表面液体脱水。在这里,我们通过引入失活突变体ENaC α mRNA(αmutENaC)来抑制内源性异源三聚体ENaC通道。脂质纳米粒携带αmutENaC转染在CF为基础的气道细胞在体外和体内。我们观察到宏观以及阿米洛利敏感的ENaC电流和CF气道细胞的气道表面液体高度的增加显着减少。同样,鼻内转染αmutENaC mRNA降低了CFTRKO小鼠对阿米洛利敏感的鼻电位差。这些数据表明,基于mRNA的ENaC抑制是减少粘液脱水的有力策略,并且具有治疗所有患者的CF的治疗潜力,与基因型无关。
A nanoparticle delivered ENaC-inhibitory mRNA for the treatment of cystic fibrosis. Cystic fibrosis (CF) results from mutations in the chloride-conducting CF transmembrane conductance regulator (CFTR) gene. Airway dehydration and impaired mucociliary clearance in CF is proposed to result in tonic epithelial sodium channel (ENaC) activity, which drives amiloride-sensitive electrogenic sodium absorption. Decreasing sodium absorption by inhibiting ENaC can reverse airway surface liquid dehydration. Here, we inhibit endogenous heterotrimeric ENaC channels by introducing inactivating mutant ENaC α mRNA (αmutENaC). Lipid nanoparticles carrying αmutENaC were transfected in CF-based airway cells in vitro and in vivo. We observed a significant decrease in macroscopic as well as amiloride-sensitive ENaC currents and an increase in airway surface liquid height in CF airway cells. Similarly, intranasal transfection of αmutENaC mRNA decreased amiloride-sensitive nasal potential difference in CFTRKO mice. These data suggest that mRNA-based ENaC inhibition is a powerful strategy for reducing mucus dehydration and has therapeutic potential for treating CF in all patients, independent of genotype.
DOI: 10.1016/s0140-6736(19)32597-8
发表时间: 2019-11-23
期刊: LANCET
影响因子: 168.9
作者:
Heijerman, Harry G. M.;McKone, Edward F.;Mccoy, Karen S.
通讯作者: Mccoy, Karen S.
DOI: 10.1183/09031936.97.10092018
发表时间: 1997-09-01
影响因子: 24.3
作者:
Ho, LP;Samways, JM;Innes, JA
通讯作者: Innes, JA
DOI: 10.1074/jbc.274.14.9648
发表时间: 1999-04-02
影响因子: 4.8
作者:
Kieber-Emmons, T;Lin, CM;Kleyman, TR
通讯作者: Kleyman, TR
DOI: 10.1523/jneurosci.21-08-02678.2001
发表时间: 2001-04-15
影响因子: 5.3
作者:
García-Añoveros, J;Samad, TA;Corey, DR
通讯作者: Corey, DR
DOI: 10.1113/jphysiol.1988.sp017322
发表时间: 1988-11-01
影响因子: 5.5
作者:
BOUCHER, RC;COTTON, CU;YANKASKAS, JR
通讯作者: YANKASKAS, JR